Table.2.
The percentage of times each of the baseline characteristics was balanced across each of the 1000 randomizations schemes in the trial population
| Baseline characteristic | Value | Constrained randomization method | ||
|---|---|---|---|---|
| Unrestricted/simple | Prognostic baseline characteristics | Principal components | ||
| Center size | Mean ± standard deviation | 32.9% | 41.8% | 38.7% |
| Composite outcome of CV-related death and major CV-related hospitalization | Rate (per 100 person-year) | 32.5% | 36.2% | 33.5% |
| Age (years) | Mean ± standard deviation | 95.3% | 99.8% | 99.2% |
| < 65 | 97.8% | 99.7% | 99.9% | |
| 65 to 74 | 100.0% | 100.0% | 100.0% | |
| 75 to 84 | 100.0% | 100.0% | 100.0% | |
| 85 to 105 | 99.5% | 100.0% | 99.9% | |
| Sex | Male | 100.0% | 100.0% | 100.0% |
| Living in a rural area | Yes | 63.0% | 84.2% | 65.8% |
| Etiology for end-stage kidney disease | Diabetes | 93.0% | 94.5% | 95.0% |
| Glomerulonephritis/autoimmune diseases | 96.3% | 100.0% | 99.5% | |
| Drug-induced nephropathy | 100.0% | 99.9% | 100.0% | |
| Polycystic kidney disease | 100.0% | 100.0% | 100.0% | |
| Renal vascular disease | 97.5% | 97.6% | 96.7% | |
| Other | 88.3% | 91.9% | 91.6% | |
| Race | Asian | 75.0% | 81.3% | 88.1% |
| Black | 73.4% | 95.9% | 91.9% | |
| White | 45.6% | 64.0% | 90.2% | |
| Other | 56.6% | 65.7% | 77.5% | |
| Unknown | 93.2% | 93.7% | 93.6% | |
| First dialysis modality | Home hemodialysis | 100.0% | 99.8% | 99.9% |
| In-center hemodialysis | 97.8% | 98.6% | 99.9% | |
| Peritoneal dialysis | 97.4% | 98.7% | 99.8% | |
| First vascular access used at dialysis start | AV graft | 99.9% | 100.0% | 100.0% |
| Fistula | 98.9% | 99.1% | 99.4% | |
| Catheter | 93.5% | 96.2% | 99.4% | |
| PD catheter | 98.8% | 99.0% | 100.0% | |
| Unknown | 92.4% | 93.8% | 94.3% | |
| Most recent vascular access before the index date | AV graft | 98.7% | 99.8% | 98.9% |
| Fistula | 91.9% | 94.8% | 97.7% | |
| Catheter | 89.9% | 94.0% | 97.4% | |
| Patients 65+ years in ODB in the 6 months prior to index date | Yes | 97.5% | 99.3% | 99.4% |
| Unique hypertensive drugs 6 months before the index date | Mean ± standard deviation | 97.1% | 99.9% | 99.5% |
| Prescribed hypertensive drugs | Angiotensin-converting enzyme (ACE) inhibitors | 99.4% | 99.3% | 99.5% |
| Angiotensin II receptor blocker | 90.7% | 96.1% | 96.9% | |
| Beta-blockers | 99.7% | 100.0% | 99.9% | |
| Calcium channel blocker | 98.1% | 100.0% | 99.6% | |
| Diuretics | 91.9% | 97.0% | 95.6% | |
| CABG/PCI | Yes | 99.4% | 99.5% | 100.0% |
| Heart failure | Yes | 96.8% | 100.0% | 99.8% |
| Diabetes mellitus | Yes | 99.0% | 100.0% | 100.0% |
| Ischemic stroke | Yes | 100.0% | 100.0% | 100.0% |
| Lower extremity amputation | Yes | 99.9% | 100.0% | 100.0% |
| Lung disease (COPD) | Yes | 99.0% | 99.6% | 100.0% |
| Myocardial infarction | Yes | 99.2% | 100.0% | 100.0% |
| Major cancer | Yes | 100.0% | 100.0% | 100.0% |
| Peripheral vascular disease | Yes | 90.7% | 97.2% | 91.4% |
| Modified Charlson comorbidity Score | Mean ± standard deviation | 96.8% | 99.9% | 100.0% |
| 2 | 97.7% | 100.0% | 100.0% | |
| 3 | 100.0% | 100.0% | 100.0% | |
| 4 | 100.0% | 100.0% | 100.0% | |
| 5+ | 98.9% | 100.0% | 100.0% | |
| Having a kidney transplant before the index date | Yes | 100.0% | 100.0% | 100.0% |
| Number of hospital admissions in the year before the index date | Mean ± standard deviation | 93.9% | 98.4% | 98.4% |
| 0 | 78.4% | 76.4% | 81.1% | |
| 1 to 3 | 99.5% | 99.6% | 99.9% | |
| 4 to 6 | 99.4% | 99.6% | 99.5% | |
| 7 to 9 | 100.0% | 99.9% | 100.0% | |
| 10+ | 92.1% | 92.0% | 94.6% | |
| Long term care facility utilization in the year before the index date | Yes | 81.3% | 86.6% | 86.1% |
| Time since the first date on dialysis (days) | Mean ± standard deviation | 88.1% | 94.0% | 94.4% |